Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company

Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China

Fineline Cube Apr 25, 2023

Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...

Company Deals

Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software

Fineline Cube Apr 25, 2023

Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...

Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Company

WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1

Fineline Cube Apr 25, 2023

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...

Company Legal / IP

SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns

Fineline Cube Apr 25, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...

Company Deals

Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development

Fineline Cube Apr 25, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...

Company Drug

GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14

Fineline Cube Apr 24, 2023

The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...

Company Drug

Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan

Fineline Cube Apr 24, 2023

China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...

Company Deals

Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million

Fineline Cube Apr 24, 2023

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor

Fineline Cube Apr 24, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies

Fineline Cube Apr 24, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...

Company

YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 24, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...

Company

LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch

Fineline Cube Apr 23, 2023

China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...

Company Deals

Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT

Fineline Cube Apr 23, 2023

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...

Company Drug

Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC

Fineline Cube Apr 23, 2023

Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...

Hospital Policy / Regulatory

China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide

Fineline Cube Apr 23, 2023

The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...

Posts pagination

1 … 534 535 536 … 667

Recent updates

  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
  • BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
  • China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases
  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.